Accurate prognosis of patients with luminal type A and HER‑2 overexpressing breast cancer via the partitioning calculation method of the Ki‑67 index

Wang,Changsong; Lv,Xuexia; Meng,Nianlong; Li,Fulin; Wang,Yaxi; Yun,Tian; Cao,Yansha; Fan,Naijun

doi:10.3892/wasj.2023.198

Accurate prognosis of patients with luminal type A and HER‑2 overexpressing breast cancer via the partitioning calculation method of the Ki‑67 index

Authors:
- Changsong Wang
- Xuexia Lv
- Nianlong Meng
- Fulin Li
- Yaxi Wang
- Tian Yun
- Yansha Cao
- Naijun Fan
View Affiliations

Affiliations: Department of Pathology, The 989th Hospital of The PLA Joint Logistic Support Force, Luoyang, Henan 471031, P.R. China
Published online on: July 5, 2023 https://doi.org/10.3892/wasj.2023.198
Article Number: 21
Copyright : © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to perform the accurate prognosis of different molecular types breast cancer (BC) by using the partitioning calculation method of the Ki‑67 index. Partitioning calculation was used to judge the Ki‑67 index and the molecular type was classified according to the 2019 Chinese Society of Clinical Oncology guidelines in 199 cases of BC. The association between the Ki‑67 index and overall survival (OS), disease‑free survival (DFS) and molecular types was analyzed using the Chi‑squared test. Survival analysis was performed using the Kaplan‑Meier method with statistical SPSS 18.0 software. The results revealed that the 5‑year survival rate of patients with BC was 18.60% (8/43), the 6‑year survival rate was 38.24% (26/68), while the 10‑year survival rate of patients with BC was 73.08% (133/182); the results indicated that almost 80% patients succumbed during the 5 years following diagnosis. Marked differences were found between the OS of patients with BC and the Ki‑67 index (between 50 to 54%) (χ²=4.83, P=0.028; χ²=4.60, P=0.032 respectively). All 14 cases of luminal A subtype BC with a Ki‑67 index ≤4% survived at the end of follow‑up time (69‑156 months). At the same time, there was a marked difference between two groups of patients with overexpression HER‑2 while using 50% as a cut‑off point of Ki‑67 (χ²=5.54, P=0.019). On the whole, the present study demonstrates that the partitioning calculation of the Ki‑67 index can be used to judge the prognosis of patients with BC accurately. The prognosis of patients with different molecular subtypes of BC may be associated with the different Ki‑67 index.

View Figures

View References

1	Jurisic V, Radenkovic S and Konjevic G: The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 867:115–124. 2015.PubMed/NCBI View Article : Google Scholar
2	Chen XY, He C, Han DD, Zhou M, Wang Q, Tian J, Li L, Xu F, Zhou E and Yang K: The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: A systematic review and meta-analysis. Future Oncol. 13:843–857. 2017.PubMed/NCBI View Article : Google Scholar
3	Erić I, Petek Erić A, Kristek J, Koprivčić I and Babić M: Breast cancer in young women: Pathologic and immunohistochemical features. Acta Clin Croat. 57:497–502. 2018.PubMed/NCBI View Article : Google Scholar
4	Li JB and Jiang ZF: Update and interpretation of 2019 guideline of Chinese Society of clinical oncology (CSCO): Breast cancer. Chin J Surg Oncol. 11:155–160. 2019.
5	Shet T: Ki-67 in breast cancer: Simulacra and simulation. Indian J Cancer. 57:231–233. 2020.PubMed/NCBI View Article : Google Scholar
6	Teichgraeber DC, Guirguis MS and Whitman GJ: Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. AJR Am J Roentgenol. 217:278–290. 2021.PubMed/NCBI View Article : Google Scholar
7	Guideline Recommendations for HER2 Detection in Breast Cancer Group. Guidelines for HER2 detection in breast cancer, the 2014 version. Zhonghua Bing Li Xue Za Zhi. 43:262–267. 2014.PubMed/NCBI(In Chinese).
8	Gerdes J, Schwarting R and Stein H: High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol. 39:993–997. 1986.PubMed/NCBI View Article : Google Scholar
9	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 24:2206–2223. 2013.PubMed/NCBI View Article : Google Scholar
10	Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y and Arima N: Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2:1062–1068. 2014.PubMed/NCBI View Article : Google Scholar
11	Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL and Boyages J: The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol. 67:222–228. 2014.PubMed/NCBI View Article : Google Scholar
12	Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T and Kurosumi M: Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer. 17(354)2017.PubMed/NCBI View Article : Google Scholar
13	Kadivar M and Aram F: Assessment of Ki67 in breast cancer: A comparison between the Eye-10 method, stepwise counting strategy, and international system of Ki67 evaluation. Iran J Pathol. 15:13–18. 2020.PubMed/NCBI View Article : Google Scholar
14	Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 23:7212–7220. 2005.PubMed/NCBI View Article : Google Scholar
15	Stuart-Harris R, Caldas C, Pinder SE and Pharoah P: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 17:323–334. 2008.PubMed/NCBI View Article : Google Scholar
16	Fulawka L and Halon A: Ki-67 evaluation in breast cancer: The daily diagnostic practice. Indian J Pathol Microbiol. 60:177–184. 2017.PubMed/NCBI View Article : Google Scholar
17	Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et al: Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011.PubMed/NCBI View Article : Google Scholar
18	Ašoklis R, Kadziauskienė A, Paulavičienė R, Petroška D and Laurinavičius A: Quantitative histopathological assessment of ocular surface squamous neoplasia using digital image analysis. Oncol Lett. 8:1482–1486. 2014.PubMed/NCBI View Article : Google Scholar
19	Kang YJ, Lee HB, Kim YG, Han J, Kim Y, Yoo TK, Lee ES, Moon HG, Noh DY and Han W: Ki-67 expression is a significant prognostic factor only when progesterone receptor expression is low in estrogen receptor-positive and HER2-negative early breast cancer. J Oncol. 2019(7386734)2019.PubMed/NCBI View Article : Google Scholar
20	Silva LRD, Vargas RF, Shinzato JY, Derchain SFM, Ramalho S and Zeferino LC: Association of menopausal status, expression of progesterone receptor and Ki67 to the clinical response to neoadjuvant chemotherapy in Luminal breast cancer. Rev Bras Ginecol Obstet. 41:710–717. 2019.PubMed/NCBI View Article : Google Scholar
21	Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, Choudhary DK, Yadav A, Koyalla VPB, Sharma M, et al: Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol. 49:329–338. 2019.PubMed/NCBI View Article : Google Scholar
22	Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B and Song X: Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med Oncol. 28 (Suppl 1):S31–S38. 2011.PubMed/NCBI View Article : Google Scholar
23	Røge R, Nielsen S, Riber-Hansen R and Vyberg M: Ki-67 proliferation index in breast cancer as a function of assessment method: A NordiQC experience. Appl Immunohistochem Mol Morphol. 29:99–104. 2021.PubMed/NCBI View Article : Google Scholar
24	Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, Liu G, Yu K, Shao Z and Wang Z: The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 10(225)2020.PubMed/NCBI View Article : Google Scholar
25	Radenkovic S, Milosevic Z, Konjevic G, Karadzic K, Rovcanin B, Buta M, Gopcevic K and Jurisic V: Lactate dehydrogenase, catalase, and superoxide dismutase in tumor tissue of breast cancer patients in respect to mammographic findings. Cell Biochem Biophys. 66:287–295. 2013.PubMed/NCBI View Article : Google Scholar